Stock Taper
SCREENER COMPARE ANY 2 STOCKS
COGT
COGENT BIOSCIENCES, INC.
NASDAQ
$34.67
▼ DOWN 6.52% (-2.42)

KEY STATISTICS

Market Cap$5.92 B
52w High$43.73
52w Low$11.60
Dividend Yield—
Frequency—
P/E-16.43
Volume1.77M
Shares Out.170.87M

COMPANY

LEADERSHIP

Andrew R. Robbins
CHIEF EXECUTIVE
Andrew R. Robbins

COMPENSATION 2026

Salary$724,554
Stock Awards$12,993,250
Incentive Plan Pay$561,600
All Other Comp.$14,000
Total$27,762,684

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 29, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
258

PRICE TARGET

Target High$55.00
Target Low$45.00
Target Median$53.50
Target Consensus$51.75

UPCOMING EARNINGS

DateNov 6, 2026
DayFriday
Rev. Est.$750.00K
NOV
6
FRI

SPLIT RECORD

DATETYPERATIO
2020-11-09Reverse1:4

PRICE

$34.67 ▼ DOWN 6.52% (−$2.42)
OVERLAYS
$34.50$35.25$36.00$36.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM34.67

About Cogent Biosciences, Inc.

https://www.cogentbio.com ↗

Cogent Biosciences, Inc., a Cambridge-based biotech founded in 2014, develops precision therapies like CGT9486 targeting KIT mutations in diseases such as systemic mastocytosis and gastrointestinal stromal tumors.

INDUSTRY

Biotechnology

A PRODUCT COGENT BIOSCIENCES, INC. IS KNOWN FOR

Bezuclastinib
Bezuclastinib

Bezuclastinib, Cogent Biosciences' leading clinical program, is a selective tyrosine kinase inhibitor targeting the KIT D816V mutation in systemic mastocytosis, with an NDA submitted and a potential US launch in late 2026.

COMPETITORS

COMPETITOR
CLDX COMPARE
NVS COMPARE
RVMD COMPARE

Revenue by Products

IconPRODUCTFY2018FY2019
Preclinical Research And Clinical Development$25M $25M

ETFS HOLDING THIS STOCK

ETFS HOLDING
152
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.01% · 5.2M
XSU.TO
0.19% · 4.3M
XBI
1.05% · 3.4M
SCHA
0.13% · 810.6K
FESM
0.16% · 291.8K
CANC
4.65% · 283.4K
LFSC
6.40% · 233.8K
XRSG.L
0.19% · 150.5K
LABU
0.72% · 122.7K
TMSL
0.11% · 93.7K
RSSL
0.19% · 79.6K
USVM
0.16% · 78.2K
JSML
0.57% · 58.1K
BBSC
0.22% · 44.7K
PRFZ
0.06% · 43.6K
OP
OPTZ
0.61% · 33.6K
GSSC
0.09% · 25.4K
BBC
0.67% · 9.5K
TILT
0.01% · 7.4K
URTY
0.07% · 6.8K
ACSG
0.45% · 6.4K
STXK
0.24% · 6.1K
MMSC
0.35% · 5.0K
BKSE
0.18% · 4.6K
ESSC
0.43% · 4.0K
RFLR
0.14% · 3.9K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
71.60%
HOLDERS
412
TOP 12 OF 412 · RANKED BY POSITION SIZE
Fmr LLC
25.7M sh · $993.86M
Blackrock, Inc.
17.4M sh · $671.55M
Vanguard Group Inc
11.5M sh · $408.99M
Deerfield Management Company, L.P. (Series C)
9.1M sh · $130M
Fairmount Funds Management LLC
9.0M sh · $319.8M
Kynam Capital Management, LP
7.9M sh · $113.25M
Rtw Investments, LP
7.6M sh · $269.68M
Blackrock Inc.
7.3M sh · $61.44M
Commodore Capital LP
7.3M sh · $104.11M
State Street Corp
7.0M sh · $269.54M
Tcg Crossover Management, LLC
6.8M sh · $97.62M
Janus Henderson Group Plc
6.0M sh · $229.63M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score1

TRADES BY CONGRESS

HOUSE TRADES
Chris Jacobs
Chris Jacobs
Purchase
2022-12-12
 Christopher L. Jacobs
Christopher L. Jacobs
Purchase
2022-12-12

INSIDER TRADES

★
DIRECTOR
Ferrante Karen Jean
Purchase · 627 shares
2026-07-01
★
DIRECTOR
Shegog Todd
Purchase · 17.9K shares
2026-06-09
★
DIRECTOR
Harwin Peter Evan
Purchase · 17.9K shares
2026-06-09
★
DIRECTOR
CAIN CHRISTOPHER W.
Purchase · 17.9K shares
2026-06-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 2
BUY 2
OUTPERFORM 2
HOLD 1
NEUTRAL 1
8 GRADES IN THE LAST 12 MONTHS
Piper Sandler OVERWEIGHT Guggenheim BUY Wedbush OUTPERFORM HC Wainwright & Co. BUY JP Morgan OVERWEIGHT Needham HOLD Baird NEUTRAL Leerink Partners OUTPERFORM

SECTORS PEERS

PEERPRICE
IBRX$8.05COMPARE
LQDA$67.69COMPARE
DNLI$24.00COMPARE
RCUS$29.21COMPARE
VRDN$23.08COMPARE
OCUL$10.36COMPARE
AGIO$33.32COMPARE
RXRX$3.34COMPARE